Edwards Lifesciences (EW) Stock Price
Edwards Lifesciences Price
Edwards Lifesciences (EW) Stock | ISIN US28176E1082 | WKN 936853. The current Edwards Lifesciences stock price is 85.85 USD (2026). Revenue is 6.87 B USD. Net income is 1.74 B USD. The P/E ratio is 28.88. Market capitalization is 50.29 B USD. Edwards Lifesciences operates in the Health sector.
Edwards Lifesciences stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Edwards Lifesciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Edwards Lifesciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Edwards Lifesciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Edwards Lifesciences Price |
|---|
Edwards Lifesciences Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Edwards Lifesciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Edwards Lifesciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Edwards Lifesciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Edwards Lifesciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Edwards Lifesciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Edwards Lifesciences stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences business model & stock analysis
Edwards Lifesciences SWOT Analysis
Strengths
- Edwards Lifesciences Corp is a leading medical technology company specializing in heart valve replacement and hemodynamic monitoring.
- Strong brand reputation and global market presence.
- Continuous investment in research and development leading to innovative product portfolio.
- Strong distribution network and strategic partnerships fostering market growth.
- Robust financial performance and strong revenue growth in recent years.
Weaknesses
- Reliance on a limited number of product offerings, with heart valve replacement being the main revenue driver.
- Vulnerability to fluctuations in healthcare policies and regulations.
- Limited presence in emerging markets compared to competitors.
- Competitive pressures from other medical device manufacturers.
Opportunities
- Growing demand for minimally invasive surgeries and transcatheter heart valve replacement.
- Increasing prevalence of cardiovascular diseases worldwide, providing a larger target market.
- Expansion into emerging markets, such as Asia-Pacific and Latin America, to tap into unexplored growth potentials.
- Potential for acquisitions and strategic partnerships to broaden the product portfolio and expand market reach.
- Rising healthcare expenditure and aging population driving the demand for advanced medical technologies.
Threats
- Intense competition within the medical device industry.
- Price pressures from reimbursement cuts and hospital budget constraints.
- Regulatory challenges and potential changes in healthcare policies.
- Economic downturns impacting overall healthcare spending.
- Potential for new entrants or disruptive technologies affecting market share.
Edwards Lifesciences Segments
Edwards Lifesciences Revenue by Segment (1/4)
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences Revenue by Segment (2/4)
3 Years
5 Years
10 Years
Max
Details
Edwards Lifesciences Revenue by Segment (3/4)
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences Revenue by Segment (4/4)
3 Years
5 Years
10 Years
Max
Details
Edwards Lifesciences Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Edwards Lifesciences Eulerpool Fair Value
Edwards Lifesciences historical P/E ratio, EBIT multiple, and P/S ratio
Edwards Lifesciences annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Edwards Lifesciences shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Edwards Lifesciences Earnings Estimates
Edwards Lifesciences Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/29/2026 | 0.75USD | 1.65 BUSD | 2026 Q1 |
| 4/21/2026 | 0.75USD | 1.65 BUSD | 2026 Q1 |
| 2/10/2026 | 0.64USD | 1.59 BUSD | 2025 Q4 |
| 4/24/2024 | 0.69USD | 1.62 BUSD | 2024 Q1 |
| 1/29/2024 | 0.66USD | 1.54 BUSD | 2023 Q4 |
| 7/26/2023 | 0.65USD | 1.45 BUSD | 2023 Q2 |
| 4/24/2023 | 0.64USD | 1.38 BUSD | 2023 Q1 |
| 1/24/2023 | 0.63USD | 1.34 BUSD | 2022 Q4 |
| 10/27/2022 | 0.64USD | 1.35 BUSD | 2022 Q3 |
| 7/28/2022 | 0.66USD | 1.42 BUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Edwards Lifesciences stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Edwards Lifesciences shareholder structure
| % | Name |
|---|---|
11.90426% | |
5.27315% | |
4.37596% | |
3.42935% | |
3.38451% | |
2.38286% | |
2.17332% | |
2.1718% | |
1.52117% | |
1.46562% |
Edwards Lifesciences Executives and Management Board
Mr. Bernard Zovighian
(57)Chief Executive Officer, Director · since 2016
Mr. Scott Ullem
(58)Chief Financial Officer, Corporate Vice President
Mr. Larry Wood
(59)Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
Mr. Donald Bobo
(63)Corporate Vice President - Strategy and Corporate Development
Mr. Daveen Chopra
(46)Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Edwards Lifesciences Supply Chain
Frequently asked questions about Edwards Lifesciences
The business model of Edwards Lifesciences Corp revolves around the development, manufacturing, and marketing of innovative heart valve treatment solutions. Edwards Lifesciences Corp specializes in transcatheter heart valves and critical care technologies, enabling minimally invasive procedures for treating structural heart disease. The company's products aim to improve patient outcomes and enhance healthcare efficiency. Edwards Lifesciences Corp's business model is driven by its commitment to research and development, strategic collaborations, global expansion, and delivering exceptional quality and value to healthcare providers. Edwards Lifesciences Corp consistently strives to meet the evolving needs of patients worldwide through its innovative solutions in the field of cardiovascular disease management.
Edwards Lifesciences stock
Edwards Lifesciences Peer Group
Edwards Lifesciences Ticker
Edwards Lifesciences FIGI
All fundamentals and in-depth analysis of Edwards Lifesciences
Our stock analysis for Edwards Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edwards Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.